A.J. Barbarito

Commentary|Articles|October 8, 2026 Author(s)Brian Nowosielski, A.J. Barbarito, Esq. In part 2 of our pre-election series, detailing key health policies for pharmacists at this year’s midterms, a legal expert touches on MFN pricing, ACA subsidies, and more. With the US midterms less than a month away, the policies that shape what pharmacies pay for drugs, what they're reimbursed, and what their patients can afford are already shifting.

How is PBM reform momentum expected to shift, if at all, after the 2026 midterms conclude? PBM reform momentum is likely to remain strong or accelerate after the midterms, regardless of which party controls Congress. The issue has unusual bipartisan support. H.R. 7895, the “PBM Kickback Prohibition Act,” was reported by the House Education and Workforce Committee in July 2026 and awaits a floor vote.

Commentary|Articles|October 6, 2026 Author(s)Brian Nowosielski, A.J. Barbarito, Esq. In part 1 of our midterm election FAQ series, AJ Barbarito, Esq, breaks down ongoing legal developments for pharmacists and what a change in Congressional control could mean for the profession. With the 2026 midterm elections just weeks away, pharmacists have more on the line than usual.